SynAct Pharma AB (FRA:8F8)

SynAct Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	27.38	40.49	44.83	35.61	16.23	8.81
Research & Development	87.86	49.31	105.06	70.07	60.49	22.79
Other Operating Expenses	-0.93	-0.14	-0.04	-0.11	-0.16	-0.31
Operating Expenses	114.3	89.67	149.84	105.57	76.56	31.29
Operating Income	-114.3	-89.67	-149.84	-105.57	-76.56	-31.29
Interest Expense	-1.77	-0.82	-0.8	-0.29	-0.11	-0.05
Interest & Investment Income	0.23	0.23	0.59	0.05	-	0.03
Currency Exchange Gain (Loss)	-0.57	-0.57	0.33	-1.25	-0.15	-
Other Non Operating Income (Expenses)	-0	-0	-0	0	-	-
EBT Excluding Unusual Items	-116.41	-90.83	-149.72	-107.07	-76.81	-31.3
Impairment of Goodwill	-	-	-74.56	-	-	-
Pretax Income	-116.41	-90.83	-224.28	-107.07	-76.81	-31.3
Income Tax Expense	-10.13	-8.42	-8.47	-7.86	-7.51	-4.75
Net Income	-106.28	-82.4	-215.81	-99.21	-69.3	-26.55
Net Income to Common	-106.28	-82.4	-215.81	-99.21	-69.3	-26.55
Shares Outstanding (Basic)	48	40	33	28	26	22
Shares Outstanding (Diluted)	48	40	33	28	26	22
Shares Change (YoY)	27.46%	21.81%	17.90%	6.72%	19.95%	43.06%
EPS (Basic)	-2.20	-2.08	-6.64	-3.60	-2.68	-1.23
EPS (Diluted)	-2.21	-2.08	-6.64	-3.60	-2.68	-1.23
EBITDA	-	-15.09	-75.26	-	-	-30.9
D&A For EBITDA	-	74.58	74.58	-	-	0.38
EBIT	-114.3	-89.67	-149.84	-105.57	-76.56	-31.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.